Imperial Prostate

A collective of expert urologists, medical specialists, and experienced researchers working to change the way the world diagnoses and treats prostate disease

[Imperial Prostate @IP_London]

🚨 NEW IN @EUplatinum! 🚨

The largest analysis of focal therapy by Imperial Prostate and UK colleagues, reporting 1⃣0⃣-year outcomes after focal HIFU and cryotherapy in 3⃣4⃣7⃣7⃣ men 🔥🧊

Led by @AJWLight @LondonProstate1 @TaimurShah

Read for free: https://t.co/BL19aINTgM

[Imperial Prostate @IP_London]

The #IP15RADAR study has now recruited 50 participants!

We are recruiting high-risk men aged 40-49 to test the best way to #screen this group for #prostatecancer.

Sign up here: https://t.co/iKG73JmeVP

[ISRCTN: the UK's Clinical Study Registry @ISRCTN]

Prostate cancer screening using short MRI and advanced blood tests in younger, high-risk men. IP15-RADAR registered at #ISRCTN by @IP_London @NikhilMayor @LondonProstate1

https://t.co/4nHQUPMX9A

#clinicaltrials

[Nikhil Mayor @NikhilMayor]

Absolutely delighted to launch the #RADAR study at @ImperialNHS to #screen younger, but higher risk men for #ProstateCancer. All men get 3 advanced tests on the same day - express your interest here: https://t.co/FeFFIHsa6H

@LondonProstate1 @IP_London @NIHRresearch

[Imperial Prostate @IP_London]

The #RADAR Study is now open!🚨

High risk men aged 40-49 will have a #Prostagram scan, a Stockholm3 test, and a PSA test to find the best way to screen for #ProstateCancer. Check if you can sign up here: https://t.co/iKG73JmeVP

@NIHRresearch @ImperialSandC @ImperialNHS

[Imperial Prostate @IP_London]

🚀 Save the date for the Imperial Prostate Masterclass 2027! #ipmasterclass27

Join leading experts from around the world for cutting-edge lectures and hands-on training sessions! 🌍🔬

📅 Friday 16 April - Saturday 17 April 2027
🎟️ Register your interest: https://t.co/gxtLII1gSB

[Sam Morris @_Sam_Morris_]

Fantastic day @ictmc2026 to see novel #AVIDITY and #TRANSFORM trial designs presented by @QMUL collaborators

IP10-AVIDITY - efficient random disclosure controlled trial design

IP12-TRANSFORM - innovative data-led strategy to widen participation in PCa screening https://t.co/bh7uA0v4LV

[Imperial Prostate @IP_London]

New milestone reached!
IP10-AVIDITY has now recruited over 50 patients.
Congratulations to @royalmarsdenNHS for recruiting the 50th patient 👏

[Patrick Gomella MD, MPH, FACS @PGomellaMD]

@EvanThomas84 Alot of great work and forward progress by our colleagues across the Pond at @IP_London @LondonProstate1

[Imperial Prostate @IP_London]

🎉 Delighted to welcome Sunderland Royal Hospital (@mccrackenstuart, Fraser Barbour) & @FreemanHospital (@rajan_vpillay, James Leighton) to #IP16SCOPE, an international service evaluation on #ActiveSurveillance in #ProstateCancer!
📩Interested? Email us: [email protected]

[Imperial Prostate @IP_London]

🚨NEW PUBLICATION🚨
IB1-LASERCOMPLETE live in @BJUIjournal!
@TUF funded prospective feasibility study in bladder cancer:
👉 Can FCM help detrusor muscle detection in TURBT samples
📄 Read it free: https://t.co/bm6QC67jT4
Thank you to the funder, all co-authors and the patients!

[Imperial Prostate @IP_London]

Great presentation of the #IB1LASERCOMPLETE results looking at #FCM for detrusor muscle detection in TURBT samples by @Archana_GK1 at #SGU2026 (St Gallen)

✅ 100% feasible to interpret FCM images
✅ High inter-observer agreement
🔍 Exploratory diagnostic performance unclear

[Imperial Prostate @IP_London]

@Archana_GK1 presented RAPID 5-year #ActiveSurveillance outcomes at @SGU2026 in St Gallen

➡️ ~50% treatment within 5 years, GG2>GG1
➡️ Treatment triggers are heterogenous
➡️ Active surveillance needs improvement
➡️ IP9-ATLAS RCT recruiting (MRI-guided vs NICE SOC surveillance)

[European Urology @EUplatinum]

📢 New publication in European Urology

We are pleased to highlight a new study published in European Urology, titled “Five-year Outcomes for Men after Negative Magnetic Resonance Imaging (MRI) or Negative Biopsy in the RAPID MRI-directed Prostate Cancer Diagnostic Pathway”.

👏 Congratulations to Chase Ng, Alexander Light, and Taimur Shah on this excellent contribution, together with all co-authors.

🔗 Read the full article here:
👉 https://t.co/qh9oFflmmE

#EuropeanUrology #Urology #UroOncology #Research #MedicalResearch #AcademicUrology

[Alexander Light @AJWLight]

Wholeheartedly recommend applying!!

[Imperial Prostate @IP_London]

📣 Calling all aspiring academic urologists: we are hiring!

Applications open soon for the 2027 @NIHRresearch Academic Clinical Fellowship in urology.

Join our 🌍-leading #ProstateCancer research group led by @LondonProstate1 💫

https://t.co/bHUuoguQwl

[Hashim U. Ahmed @LondonProstate1]

Reasonable precis of some of my work

You omitted another relevant bit though

The TRANSFORM screening RCT (that I am Chief Investigator for) in which focal therapy is mandated in the screening arms (n=150-300K) (£60M from @ProstateUK & UK National Institute for Health Research

[Focal Therapy Society @FocalSociety]

Deep respect to @LondonProstate1 Prof. Hashim Ahmed for his unwavering commitment to advancing prostate cancer care. Designing and executing RCTs comparing focal ablation to whole-gland radical treatment is notoriously difficult due to patient preferences and recruitment hurdles. Yet, he remains one of the few investigators in the world actually leading multiple prospective RCTs in this space allowing us to build the evidence base we all rely upon.

[Rafael Sanchez-Salas @RSanchez_Salas]

Dear @LondonProstate1
Leadership often comes with scrutiny, and with unfair criticism. It is difficult to witness someone who has dedicated so much to advancing patient care, research, education, and innovation become the target of personal attacks and coordinated hostility.

[Imperial Prostate @IP_London]

#IP10AVIDITY update after a strong July for recruitment

4⃣0⃣ patients recruited from 2 main sites and 2 PICs

New sites opening soon helping to answer PSMA PET clinical utility and cost-effectiveness questions

Thanks to all patients and all those involved

[Peter Ka-Fung CHIU @peterchiu_uro]

Hot off the press!

Our initial experience with the novel Intilume system (Agilis Robotics, Hong Kong) for Robotic en bloc resection of bladder tumor with 2 fully flexible robotic arms (3.2mm) !

European Urology article:
https://t.co/3zrSlmtLMt

Video: https://t.co/rDZofTCXlF